These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 14666910)

  • 1. Warning against tenofovir + ddI + 3TC, and "triple nuke" combinations.
    AIDS Treat News; 2003 Oct; (395):2-3. PubMed ID: 14666910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents.
    Gulick R
    AIDS; 1998; 12 Suppl 3():S17-22. PubMed ID: 15168719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
    Sax PE
    AIDS Clin Care; 2005 Jan; 17(1):6-7. PubMed ID: 15717372
    [No Abstract]   [Full Text] [Related]  

  • 4. FTC (emtricitabine, Emtriva).
    Proj Inf Perspect; 2003 Oct; (36):6-7. PubMed ID: 14696567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.
    Kakuda TN; Anderson PL; Becker SL
    AIDS; 2004 Dec; 18(18):2442-4. PubMed ID: 15622326
    [No Abstract]   [Full Text] [Related]  

  • 7. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.
    Brogly SB; Ylitalo N; Mofenson LM; Oleske J; Van Dyke R; Crain MJ; Abzug MJ; Brady M; Jean-Philippe P; Hughes MD; Seage GR
    AIDS; 2007 May; 21(8):929-38. PubMed ID: 17457086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial comment: tenofovir-related nephrotoxicity--who's at risk?
    Gupta Samir K
    AIDS Read; 2007 Feb; 17(2):102-3. PubMed ID: 17323509
    [No Abstract]   [Full Text] [Related]  

  • 9. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
    Prescrire Int; 2004 Oct; 13(73):180-2. PubMed ID: 15499699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
    Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
    Muñoz de Benito RM; Arribas López JR
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):523-35. PubMed ID: 17009933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread) -- and warning on Viagra, Cialis, and Levitra.
    AIDS Treat News; 2004 Mar; (399):5. PubMed ID: 15199867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
    Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial comment: mixing tenofovir with other nephrotoxins--how safe is this?
    Gupta SK
    AIDS Read; 2009; 19(6):246. PubMed ID: 19642244
    [No Abstract]   [Full Text] [Related]  

  • 15. A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.
    Fox Z; Dragsted UB; Gerstoft J; Phillips AN; Kjaer J; Mathiesen L; Youle M; Katlama C; Hill A; Bruun JN; Clumeck N; Dellamonica P; Lundgren JD;
    Antivir Ther; 2006; 11(6):761-70. PubMed ID: 17310820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
    [No Abstract]   [Full Text] [Related]  

  • 17. To nuke, or not to nuke?
    Proj Inf Perspect; 2007 Apr; (43):1-3. PubMed ID: 17684823
    [No Abstract]   [Full Text] [Related]  

  • 18. Cutaneous reactions with tenofovir disoproxil fumarate: a report of nine cases.
    Lockhart SM; Rathbun RC; Stephens JR; Baker DL; Drevets DA; Greenfield RA; Salvaggio MR; Vincent S
    AIDS; 2007 Jun; 21(10):1370-3. PubMed ID: 17545718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.
    Damond F; Matheron S; Peytavin G; Campa P; Taieb A; Collin G; Delaunay C; Chêne G; Brun-Vézinet F; Descamps D
    Antivir Ther; 2004 Aug; 9(4):635-6. PubMed ID: 15456096
    [No Abstract]   [Full Text] [Related]  

  • 20. Lessons from two "triple nuke" failures (new training module).
    AIDS Treat News; 2004 Mar; (399):6. PubMed ID: 15199869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.